A nickel-catalyzed process that converts biodegradable PLA and PHA polymers into valuable N-alkylated amines and CO2-derived carbamic acids. Using a responsive phosphine 1-azaallyl (P^AzA) ligand system, the technology enables sequential decarboxylation and alkyl transfer, offering a new recycling pathway distinct from conventional transesterification approaches.
This research presents a catalytic depolymerization platform that transforms biodegradable polyesters (PLA and PHA) into high-value chemical products rather than low-value recyclates. The approach uses an earth-abundant nickel catalyst combined with a structurally responsive phosphine 1-azaallyl (P^AzA) ligand to achieve sequential decarboxylation and alkyl transfer from the polymer chain. Each monomeric unit yields two valuable molecular fragments: N-alkylated amines and CO2 sequestered as carbamic acids that can be readily separated by pH-controlled extraction. This offers a distinct alternative to conventional PLA/PHA recycling methods that rely on transesterification or reductive deoxygenation, potentially improving the economics and sustainability profile of biopolymer waste streams.
Key features:
This technology is at an early-stage proof-of-concept phase. The P^AzA ligand family has been structurally characterized and validated across multiple metal systems (nickel, palladium, ruthenium), and related small-molecule decarboxylation and alkyl transfer steps have been demonstrated. The team possesses demonstrated expertise in nickel chemistry, ligand/catalyst design, and polymer manipulation. Next steps involve synthesizing a family of NiX(P^AzA) complexes with varied ligand and anionic ligand combinations, followed by parallel validation through small-molecule model studies and direct catalytic depolymerization of PLA/PHA. The technology is not yet commercially deployed and requires further catalyst optimization and scale-up validation before industrial readiness.
Western University is a comprehensive public research university in London, Ontario, with a full spectrum of professional and research programs and a strong culture of partnership with industry. Companies engage through co-located labs and shared core facilities, a research and technology park with industry tenancy, and advanced prototyping testbeds that enable scale-up. Integration with major hospital systems and affiliated research institutes supports clinical translation and trials, while co-op and internship pathways provide reliable talent pipelines. Research is backed by competitive funding from NSERC, CIHR, SSHRC, and the Canada Foundation for Innovation, and a dedicated technology transfer office offers IP strategy, licensing, and startup support.